Down-Regulation of HLA Class I Antigens in Prostate Cancer Tissues and Up-Regulation by Histone Deacetylase Inhibition

Journal of Urology

Volumn 178, Issue 2, 2007, Pages 692-696

  Kitamura, Hiroshi ^a   Torigoe, Toshihiko ^a   Asanuma, Hiroko ^a   Honma, Ichiya ^a   Sato, Noriyuki ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

beta 2 microglobulin; histocompatibility antigens class I; prostate; prostatic neoplasms; trichostatin A

Indexed keywords

BETA 2 MICROGLOBULIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H3 ANTIBODY; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; EPIGENETICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; PROSTATE; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 34447102893     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.109     Document Type: Article

References (16)

1. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909
2. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999
3. Marincola F.M., Jaffee E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74 (2000) 181
4. Seliger B., Cabrera T., Garrido F., and Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12 (2002) 3
5. Prostate. In: Greene F.L., Page D.L., Flemming I.D., Fritz A., Balch C.M., Haller D.G., et al. (Eds). AJCC Cancer Staging Manual. 6th ed. (2002), Springer, New York 309-316
6. Kitamura H., Torigoe T., Honma I., Asanuma H., Nakazawa E., Shimozawa K., et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 67 (2006) 955
7. Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y., Shimozawa K., et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64 (2004) 5442
8. Blades R.A., Keating P.J., MaWilliam L.J., George N.J., and Stern P.L. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46 (1995) 681
9. Zhang H., Melamed J., Wei P., Cox K., Frankel W., Bahnson R.R., et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immunol 3 (2003) 2
10. Webster W.S., Small E.J., Rini B.I., and Kwon E.D. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 32 (2005) 8262
11. Sanda M.G., Restifo N.P., Walsh J.C., Kawakami Y., Nelson W.G., Pardoll D.M., et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87 (1995) 280
12. Huang W.C., Wu D., Xie Z., Zhau H.E., Nomura T., Zayzafoon M., et al. β2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66 (2006) 9108
13. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923
14. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166
15. Richon V.M. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95 (2006) S2
16. O'Connor O.A. Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 95 (2006) S7